MetaCap

Mineralys Therapeutics (MLYS) vs OPKO Health (OPK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

OPKO Health (OPK) has outperformed Mineralys Therapeutics (MLYS) over the past year, gaining 18.9% versus a loss of 67.4%. Mineralys Therapeutics is the larger company by market cap ($1.21 billion vs $1.17 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MLYS-67.38%OPK+18.94%
+39%-17%-72%
Nov 21, 20251 yearNov 20, 2026
MLYS-25.92%OPK+25.60%
+146%+35%-76%
Feb 6, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MLYS versus OPK key metrics
MetricMLYSOPK
Share price$13.66$1.57
Market cap$1.21B$1.17B
1-day change-3.53%-2.48%
YTD return-62.36%+24.60%
1-year return-67.38%+18.94%
5-year return—-61.99%
EPS (TTM)$-4.30$-0.16
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$606.88M
Revenue growth (YoY)—-14.90%
Net income (latest FY)$-154.65M$-225.68M
Gross margin—33.93%
Operating margin—-19.35%
Net margin—-37.19%
52-week high$44.13$1.86
52-week low$13.57$0.98
Distance from 52-week high-69.05%-15.59%
Analyst consensusstrong_buybuy
Avg. price target upside+218.89%+164.33%
Average volume1.55M3.83M
Shares outstanding88.56M742.51M
Employees762,275
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OPK has outperformed MLYS by 86.3 percentage points over the past year.

About Mineralys Therapeutics

MLYS stock →

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

About OPKO Health

OPK stock →

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 2,275 employees

MLYS vs OPK FAQ

Which is bigger, Mineralys Therapeutics or OPKO Health?

Mineralys Therapeutics (MLYS) is larger, with a market capitalization of $1.21B compared with $1.17B for OPKO Health (OPK).

Which stock has performed better over the past year, MLYS or OPK?

OPK returned +18.94% over the past 12 months, compared with -67.38% for MLYS (price return, excluding dividends). Past performance does not predict future results.

Are Mineralys Therapeutics and OPKO Health in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons